Originally developed for the management of obesity and type 2 diabetes, GLP-1 agonists have recently been tested in populations with both obesity and OSA, showing encouraging results in reducing OSA severity through weight loss and possibly other mechanisms. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.